Alternative splicing and cancer metastasis: prognostic and therapeutic applications

The Expanding Landscape of Alternative Splicing Variation in Human Populations

(2018) Eddie Park et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Abstract P1-05-02: CRISPR/Cas9-guided editing of spliceosome factors enhances major histocompatibility complex proteins in triple-negative breast cancer

(2018) MA Bustos et al.   CANCER RESEARCH

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

(2018) Michael Seiler et al.   NATURE MEDICINE

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

(2017) Kim N Chi et al.   LANCET ONCOLOGY

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

(2017) Tomasz M Beer et al.   LANCET ONCOLOGY

EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression

(2017) Davide Pradella et al.   Molecular Cancer

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

(2017) Niclas E. Bengtsson et al.   Nature Communications

Successful correction of hemophilia by CRISPR/Cas9 genome editingin vivo: delivery vector and immune responses are the key to success

(2016) Tuan Huy Nguyen et al.   EMBO Molecular Medicine

Therapeutic targeting of splicing in cancer

(2016) Stanley Chun-Wei Lee et al.   NATURE MEDICINE

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression

(2016) Andrew P. Feinberg et al.   NATURE REVIEWS GENETICS

Splicing-factor alterations in cancers

(2016) Olga Anczuków et al.   RNA

Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage

(2016) Samar Alsafadi et al.   Nature Communications

Modulation of Alternative Splicing with Chemical Compounds in New Therapeutics for Human Diseases

(2015) Kenji Ohe et al.   ACS Chemical Biology

SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

(2015) Eunhee Kim et al.   CANCER CELL

Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo

(2015) Cara Lunn Shirai et al.   CANCER CELL

A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes

(2015) Q. Zhou et al.   CANCER RESEARCH

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling

(2015) Raul Torres-Ruiz et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth

(2015) Michael Dewaele et al.   JOURNAL OF CLINICAL INVESTIGATION

SRSF1-Regulated Alternative Splicing in Breast Cancer

(2015) Olga Anczuków et al.   MOLECULAR CELL

Spinal muscular atrophy—recent therapeutic advances for an old challenge

(2015) Irene Faravelli et al.   Nature Reviews Neurology

Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA Splicing

(2015) Shinsuke Araki et al.   PLoS One

Disease-associated mutation inSRSF2misregulates splicing by altering RNA-binding affinities

(2015) Jian Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The alternative role of DNA methylation in splicing regulation

(2015) Galit Lev Maor et al.   TRENDS IN GENETICS

Deregulation of splicing factors and breast cancer development

(2015) Marco Silipo et al.   Journal of Molecular Cell Biology

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

(2015) Rachel B. Darman et al.   Cell Reports

Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers

(2015) Christopher DeBoever et al.   PLoS Computational Biology

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma

(2014) M V Gammons et al.   BRITISH JOURNAL OF CANCER

Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia

(2014) Justin J.-L. Wong et al.   CANCER SCIENCE

Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ

(2014) H Solomon et al.   CELL DEATH AND DIFFERENTIATION

Antisense oligonucleotides in cancer

(2014) Daniela Castanotto et al.   CURRENT OPINION IN ONCOLOGY

U2AF1mutations alter splice site recognition in hematological malignancies

(2014) Janine O. Ilagan et al.   GENOME RESEARCH

Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) Suppress Cancer Cell Motility via Different Mechanisms

(2014) Hiroki Ishii et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing

(2014) Henrike Maatz et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting Cdk11 in osteosarcoma cells using the CRISPR-cas9 system

(2014) Yong Feng et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing

(2014) T Okeyo-Owuor et al.   LEUKEMIA

Emerging Functions of SRSF1, Splicing Factor and Oncoprotein, in RNA Metabolism and Cancer

(2014) S. Das et al.   MOLECULAR CANCER RESEARCH

A day in the life of the spliceosome

(2014) A. Gregory Matera et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome

(2014) Diego M. Marzese et al.   Pigment Cell & Melanoma Research

Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties

(2014) X He et al.   Oncogenesis

Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic

(2014) Pedro M. D. Moreno et al.   Frontiers in Chemistry

The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome

(2013) Kelly A. Avery-Kiejda et al.   CARCINOGENESIS

Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer

(2013) Pengnan Zhang et al.   CARCINOGENESIS

Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition

(2013) Alika K Maunakea et al.   CELL RESEARCH

Regulation of splicing by SR proteins and SR protein-specific kinases

(2013) Zhihong Zhou et al.   CHROMOSOMA

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

(2013) F. A. L. M. Eskens et al.   CLINICAL CANCER RESEARCH

Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy

(2013) Taeyoung Koo et al.   HUMAN GENE THERAPY

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

(2013) D. S. Hong et al.   INVESTIGATIONAL NEW DRUGS

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3

(2013) Marcel Martin et al.   NATURE GENETICS

Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma

(2013) J William Harbour et al.   NATURE GENETICS

Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms

(2013) H.-L. Zhou et al.   NUCLEIC ACIDS RESEARCH

Hallmarks of alternative splicing in cancer

(2013) S Oltean et al.   ONCOGENE

Misregulation of Pre-mRNA Alternative Splicing in Cancer

(2013) J. Zhang et al.   Cancer Discovery

SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts

(2012) Michael C. Ryan et al.   BIOINFORMATICS

Regulated Noise in the Epigenetic Landscape of Development and Disease

(2012) Elisabet Pujadas et al.   CELL

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

(2012) Andrew V. Biankin et al.   NATURE

The spliceosome as a target of novel antitumour drugs

(2012) Sophie Bonnal et al.   NATURE REVIEWS DRUG DISCOVERY

RNA therapeutics: beyond RNA interference and antisense oligonucleotides

(2012) Ryszard Kole et al.   NATURE REVIEWS DRUG DISCOVERY

Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT)

(2012) Claude C. Warzecha et al.   SEMINARS IN CANCER BIOLOGY

Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell

(2012) Toshifumi Yae et al.   Nature Communications

S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1

(2012) Vered Ben-Hur et al.   Cell Reports

Shuttling SR proteins: more than splicing factors

(2011) Laure Twyffels et al.   FEBS Journal

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

(2011) Víctor Quesada et al.   NATURE GENETICS

Histone H3 lysine 9 trimethylation and HP1γ favor inclusion of alternative exons

(2011) Violaine Saint-André et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Antitumorigenic potential of STAT3 alternative splicing modulation

(2011) F. Zammarchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of SAP155 as the Target of GEX1A (Herboxidiene), an Antitumor Natural Product

(2010) Makoto Hasegawa et al.   ACS Chemical Biology

An ESRP-regulated splicing programme is abrogated during the epithelial–mesenchymal transition

(2010) Claude C Warzecha et al.   EMBO JOURNAL

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged

(2010) C. J. David et al.   GENES & DEVELOPMENT

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

(2010) Kim N. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: Therapeutic potential of bifunctional oligonucleotides and indole derivatives

(2010) Claudia Ghigna et al.   RNA Biology

Regulation of Alternative Splicing by Histone Modifications

(2010) R. F. Luco et al.   SCIENCE

Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines

(2009) Hannah C. Cheung et al.   BRAIN

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma

(2009) Asher A. Chanan-Khan et al.   LEUKEMIA & LYMPHOMA

ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 Splicing

(2009) Claude C. Warzecha et al.   MOLECULAR CELL

The SR protein family of splicing factors: master regulators of gene expression

(2008) Jennifer C. Long et al.   BIOCHEMICAL JOURNAL

Alternative isoform regulation in human tissue transcriptomes

(2008) Eric T. Wang et al.   NATURE